Content area

|
|

Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Ekkokardiografisk billede til udregning af myokardiets forkortningsfraktion, hvilket primært bruges i forskningssammenhæng inden for kardioonkologien.
Forfatter(e)
Ann Banke1, Anne Polk2, Dorte Nielsen2, Lars Videbæk1, Ulrik Overgaard3, Emil Loldrup Fosbøl4, Merete Vaage-Nielsen5, Kirsten Melgaard Nielsen6 & Morten Schou5 1. Hjertemedicinsk Afdeling, Odense Universitetshospital 2. Onkologisk Afdeling, Herlev og Gentofte Hospital 3. Klinik for Blodsygdomme, Rigshospitalet 4. Hjertemedicinsk Afdeling, Rigshospitalet 5. Kardiologisk Afdeling, Herlev og Gentofte Hospital 6. Afdeling for Hjertesygdomme, Aarhus Universitetshospital Ugeskr Læger 2018;180:V04170269
Reference: 
Ugeskr Læger 2018;180:V04170269
Blad nummer: 
Sidetal: 
2-6
Management of cardiovascular complications secondary to medical treatment of cancer
As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer
af Frank Bang Nissen | 15/10
1 Kommentar
af Peter Hvidbak Revald | 14/10
3 kommentarer
af Arne Mejlhede | 11/10
1 Kommentar
af Sven Refslund Poulsen | 06/10
3 kommentarer